# US 2016/0354441 A1 · Non-surgical, localized delivery of compositions for placental growth factors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354441 A1
- Document ID: US20160354441A1
- Status: Published application
- Kind: A1
- Application number: 14/845,199
- Filed: 2015-09-03
- Published: 2016-12-08
- Earliest claimed: 2013-01-17
- Assignees: MiMedx Group, Inc.
- Applicants: MiMedx Group, Inc.
- Inventors: Thomas J. Koob; Rebeccah J. C. Brown
- Web page: https://patentgrep.com/patent/US20160354441A1

## CPC

- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61L 27/227: {Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24}
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 27/50: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- A61K 2035/126: {Immunoprotecting barriers, e.g. jackets, diffusion chambers}
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/30: Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
- A61L 2300/414: Growth factors
- A61L 2400/06: Flowable or injectable implant compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Described herewith are compositions comprising placental growth factors and methods for non-surgical, localized delivery thereof. The composition is delivered to a diseased or injured organ and/or body part and is formulated in a manner which allows for localized retention of the composition at the site of delivery.

## Claims

### Claim 1

A composition comprising a sufficient amount of placental growth factors to treat a diseased or injured organ and a body part wherein said composition is in the form of a localized bioerodible mass when applied to or proximate to said diseased or injured organ or body part, wherein said composition further comprises micronized placental tissue particles capable of being filtered through a sieve having a pore size from about 500 μm to about 10 μm.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a localization agent.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the localization agent is a thixotropic agent, or a phase changing agent.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the thixotropic agent is selected from the group consisting of hyaluronic acid, collagen, thrombin gels, fibrin gels and fibrin glues.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the phase changing agent is selected from the group consisting of a gel forming agent.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the gel forming agent is a copolymer or tripolymer of oxyethylene and oxypropylene units.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the localization agent is selected from the group consisting of a hydrogel, a polymer, and a collagen gel.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the micronized placental tissue particles capable of being filtered through a sieve having a pore size from about 300 μm to about 10 μm.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the micronized placental tissue particles capable of being filtered through a sieve having a pore size from about 250 μm to about 25 μm.

### Claim 10

A method for preparing a composition for localized delivery of placental growth factors, comprising combining an aqueous suspension of micronized placental tissue particles, the micronized placental tissue particles are capable of being filtered through a sieve having a pore size from about 500 μm to about 10 μm, an aqueous solution of placental growth factors, and a sufficient amount of a localization agent, whereby the composition is locally retained at the site of delivery upon administration.
